Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

Clinical trials sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd., explained in plain language.

Now part of Shanghai Pharmaceuticals Holding Co., Ltd. 601607 SSE

A subsidiary focused on biological therapy development.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet recruiting 1

New cell therapy B019 takes on tough lymphoma in first human trial

Disease control Not yet recruiting

This early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.

Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Disease control

Last updated Aug 16, 2026 00:00 UTC